Ekso Bionics (EKSO)
(Delayed Data from NSDQ)
$1.21 USD
-0.04 (-3.20%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.20 -0.01 (-0.83%) 6:52 PM ET
2-Buy of 5 2
D Value B Growth F Momentum D VGM
Brokerage Reports
Ekso Bionics Holdings, Inc. [EKSO]
Reports for Purchase
Showing records 21 - 35 ( 35 total )
Company: Ekso Bionics Holdings, Inc.
Industry: Medical - Instruments
Label Expansion Bodes Well for Long-Term Growth; Increased PT to $12; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Ekso Bionics Holdings, Inc.
Industry: Medical - Instruments
Multi-Unit Network Strategy Could Drive Growth; Adjusting PT to $8; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Ekso Bionics Holdings, Inc.
Industry: Medical - Instruments
Pre-announced Record 4Q19 Bodes Well For Continued Growth in 2020; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Ekso Bionics Holdings, Inc.
Industry: Medical - Instruments
Growth Momentum Continues Delivering Strongest 3Q; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Ekso Bionics Holdings, Inc.
Industry: Medical - Instruments
We are initiating coverage with Buy rating and a 12-month price target of $1.20 per share
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Ekso Bionics Holdings, Inc.
Industry: Medical - Instruments
We are dropping coverage to better allocate resources within our coverage universe.
Provider: H.C. Wainwright & Co., Inc.
Company: Ekso Bionics Holdings, Inc.
Industry: Medical - Instruments
Ramping Sales and Marketing; 2Q16 Results Update
Provider: H.C. Wainwright & Co., Inc.
Analyst: DAYAL A
Company: Ekso Bionics Holdings, Inc.
Industry: Medical - Instruments
Company: Ekso Bionics Holdings, Inc.
Industry: Medical - Instruments
4Q15 Quarterly Results Update; Era Under New Leadership Begins
Provider: H.C. Wainwright & Co., Inc.
Analyst: DAYAL A
Company: Ekso Bionics Holdings, Inc.
Industry: Medical - Instruments
New Leadership to Focus on Commercial Expansion; Maintain Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: DAYAL A
Company: Ekso Bionics Holdings, Inc.
Industry: Medical - Instruments
Industrial Segment Commercialization and 510(k) Clearance Are Near-Term Catalysts; Maintain Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: DAYAL A
Company: Ekso Bionics Holdings, Inc.
Industry: Medical - Instruments
Healthy 2Q15 Results; Contribution from Industrial Suits May Happen Faster; Maintain Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: DAYAL A
Company: Ekso Bionics Holdings, Inc.
Industry: Medical - Instruments
New York Sales Demo Reinforces Positive Outlook
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: DAYAL A
Company: Ekso Bionics Holdings, Inc.
Industry: Medical - Instruments
Unnecessary Volatility Created By Anonymous Article; Maintaining Buy Rating
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: DAYAL A
Company: Ekso Bionics Holdings, Inc.
Industry: Medical - Instruments
Commercializing the Next Generation of Human Augmentation Systems; Initiating Coverage with a Buy
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: DAYAL A